KNOWLEDGE BANK

Interviews

Bioquell Asia Pacific,

Managing Director
Bioquell Asia Pacific based in Singapore in April to be the regional office for our activities in Asia and Australasia I am responsible for the development of our business throughout the region and for the success and profitability of our activities We provide equipment and services for environmental biodecontamination across the pharmaceutical therapeutic development

Articles

Alpha-fetoprotein as a Shuttle for Medicines

Pregnancy is a natural phenomenon that ensures the survival of the species The suppression of the immune response in pregnancy is robust since the embryo cells have half the fathers proteins that should be recognised by the mothers immune system as foreign Even surrogate motherhood is possible with no genetic relationship to the embryo at all The embryo cell is turning

Research Insights

Validated Spectrometric Determination Of Penciclovir And Entecavir In Bulk And In Pharmaceutical Preparations

Abstract Simple rapid and sensitive spectroscopic methods were developed and validated for the determination of antiviral agents namely penciclovir PCV and entecavir ETV The first method is based on measuring the native fluorescence of each of the cited drugs at its optimum excitation and emission wavelengths The fluorescence intensity was measured for PCV

Case Studies

Remarkable Regression Of A Giant Cell Tumor Of The Cervical Spinetreated Conservatively With Denosumab: A Case Study

Abstract This case study has been conducted to establish the fact that Denosumab can be used as an adjuvant therapy by which to avoid or reduce the risks and morbidity of surgical treatment in patients with spinal GCTs extending into the nearby tissues considering the adequate duration safety and lack of adverse events of this treatment even though further

Techno Trends

Daiichi Sankyo and Merck Introduce Breakthrough Ifinatamab Deruxtecan for the Treatment of ES-Small Cell Lung Cancer

Daiichi Sankyo and Merck have introduced ifinatamab deruxtecan as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of adult patients with pretreated extensivestage small cell lung cancer ESSCLC

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

3D Printing Revolutionising Nanotechnology

Mansi Athalye

Mansi Athalye is Assistant Professor in Department of Pharmaceutics at L. M. College of Pharmacy, India with approx. 10 years of teaching and research experience. She has published 12 papers in international and national journals and has presented 22 papers in various conferences as author and co-author with 1 Indian Patent granted in 2018.

 

Sagar Popat

Sagar Popat is research student pursuing M. Pharmacy in Pharmaceutics at L. M. College of Pharmacy. He has worked on the topic ‘Cataract of goat eye lens by Invitro and Ex-vivo method’. He has published 1 research article and has won 1st prize in oral presentation at national level conference.

 

2

Biologics at Scale

Surbhi Gupta

Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Personalized Therapeutics program, focusing on next-generation modalities and precision medicine. Her expertise spans market analytics, forecasting, and competitive benchmarking, supporting strategic decision-making for global clients. Recognised as a trusted growth advisor, helping stakeholders navigate disruption, accelerate innovation, and capture transformative growth opportunities across the evolving biopharma landscape.

3

Peptide-Drug Conjugates in Precision Oncology

Dr. Keykavous Parang

Dr. Keykavous Parang is a professor at Chapman University with expertise in peptide-based therapeutics and targeted drug delivery systems. He has published extensively in bioconjugate chemistry and nanomedicine, focusing on translating innovative molecular platforms into clinically viable cancer treatments.

Thuy Do

Thuy Do is a Pharm.D. student at Chapman University School of Pharmacy with research interests in nanomedicine and cancer therapeutics. She is involved in Dr. Parang’s capstone project, focusing on peptide-based conjugates and nanoparticle drug delivery systems for the development of innovative targeted cancer treatments.

Clare Dinh

Clare Dinh ('27) is a second-year PharmD student at Chapman University with a leadership emphasis. Active in various professional organizations, she is passionate about pharmaceutical research and plans to pursue postgraduate residency or fellowship programs to further her professional career.

Mahsa Moazen

Mahsa Moazen is a PharmD student at Chapman University and a researcher in Dr. Parang’s peptide drug conjugates project. She earned her bachelor’s degree in Pharmaceutical Chemistry. Her academic interests focus on peptide conjugates for targeted cancer therapy, bridging pharmaceutical research and clinical practice to advance innovative drug development.”

Troy Khong

Troy Khong is a PharmD student at Chapman University School of Pharmacy, set to graduate with a Pharm.D. with a Leadership Degree Emphasis in 2027. I am excited to continue growing in the field of pharmacy and look forward to pursuing opportunities related to pharmaceutical industry.

4

APAC’s Rising Role in Neurodegenerative Disease Research and Development

Simona Lambertini

Simona Lambertini is a senior global clinical research leader with nearly 20 years of experience in international clinical development, research strategy and stakeholder engagement. She has led complex multicountry programs across Europe, North America and the Middle East, collaborating with pharma, biotech and research institutions across high-complexity therapeutic areas.

5

Covid -19 and Nanoparticles

Ramendra Pati Pandey

Ramendra Pati Pandey is an Assistant Professor in the Department of Biotechnology/Microbiology/Biomedical Engineering at the SRM University, Delhi-NCR, Sonepat. He was a FAPESP Post-Doctoral Fellow a very prestigious fellowship of Latin America at the Department of Medicine-InCor/HC-FMUSP, University of Sao Paulo, Brazil.

 

Deepika

Deepika has completed here master degree from Department of Biotechnology, Deenbandhu Choturam University and Technology, Sonepat, Haryana, India.

 

Reshma

Reshma completed her master's degree from the Royal Global University in Guwahati, Assam, India's department of Biotechnology.

 

Neehasri

Neehasri holds a master's degree in Zoology from Gauhati University in Guwahati, Assam, India, and has also passed the B.Ed. professional exam.

 

press releasesRead more...

Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea (aflibercept), in Canada

Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA and Samsung Bioepis Co Ltd today announced that the companies have entered into a license and commercialization agreement for OPUVIZ aflibercept

WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy

WuXi Biologics HK a leading global Contract Research Development and Manufacturing Organization CRDMO announced that its MFG drug substance manufacturing facility located in Hebei

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

Everest Medicines HKEX HK announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics Inc NASDAQ TVTX for the development

Fischer Medical Ventures Highlights Strategic Partnership as NYB.AI Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited FMVL today announced that its strategic partner Nanyang Biologics has achieved a significant international milestone with its AIpowered molecular research platform NYBAI

RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers

RoslinCT a leading global cell therapy Contract Development and Manufacturing Organization today announced a strategic partnership with BlueRock Therapeutics a leader in stem cell therapeutic development

Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations

Merck a leading science and technology company today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active

EventsRead more...

16 - 19

Jul 2026

Bio Asia Taiwan 2026

Taipei Nangang Exhibition Cent...

20 - 22

Jul 2026

6th mRNA-Based Therapeutics Summit

The Westin Boston Seaport Dist...

20 - 22

Jul 2026

24 - 25

Jul 2026

26 - 30

Jul 2026

ADLM 2026

Anaheim, CA USA

27 - 28

Jul 2026

27 - 28

Jul 2026

27 - 28

Jul 2026

LATEST NEWSRead more...

Samsung Bioepis Enters into Agreement with Proteina for AI-Based Antibody Therapeutics Development

Samsung Bioepis has entered into a licence agreement with Proteina to collaborate on a governmentsupported national research and development RD initiative focused on developing artificial intelligence AIbased antibody therapeutics

Teva Enters into Agreement with Polpharma Biologics for Ocrelizumab Biosimilar Candidate

Teva Pharmaceuticals and Polpharma Biologics have entered into a global licensing agreement under which Teva will receive exclusive rights to commercialise both intravenous and subcutaneous formulations

Evogene and Tel Aviv University Launch AI-Driven Small-Molecule Drug Discovery Initiative

Evogene has entered into a strategic collaboration with the Blavatnik Center for Drug Discovery BCDD at Tel Aviv University to accelerate AIdriven smallmolecule drug discovery

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

Certara Inc a global leader in modelinformed drug development is partnering with NVIDIA to advance Certaras open integrated AI platform unifying its scientific software regulatory expertise and proprietary datasets

Bayer Enters into Partnership with University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado to Advance Drug Development and Clinical Trials

Bayer has formed a strategic partnership with the University of Colorado Anschutz UCHealth and Childrens Hospital Colorado to strengthen clinical research and accelerate drug development

OTR Therapeutics Enters into Collaboration with LG Chem to Advance Oncology Drug Development

OTR Therapeutics has entered into a strategic collaboration with LG Chem to identify evaluate and develop innovative oncology therapies originating from China The partnership aims to accelerate the development of promising cancer treatments